Robert Dufour

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter et al. · New England Journal of Medicine · 2017 · 977 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 751 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Evan A. Stein, Dan Gipe, Jean Bergeron et al. · The Lancet · 2012 · 579 citations

Medicine, Pharmacology, Pharmacotherapy +17

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet et al. · European Heart Journal · 2015 · 534 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The development of lexical fluency in a second language

Judith F. Kroll, Erica Michael, Natasha Tokowicz et al. · Second language Research · 2002 · 324 citations

Language Studies, French, Linguistics +16